Medicare Enrolled

Dr. Suneet Grewal, M.D.

Rheumatology · West Hollywood, CA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Speaking/Promotional
8700 BEVERLY BLVD, West Hollywood, CA 90048
3104234496
In practice since 2011 (14 years)
NPI: 1811264476 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Grewal from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Grewal? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Grewal

Dr. Suneet Grewal is a rheumatology specialist in West Hollywood, CA, with 14 years of NPI registration. Based on federal Medicare data, Dr. Grewal performed 262,760 Medicare services across 863 unique beneficiaries.

Between the years covered by Open Payments, Dr. Grewal received a total of $336,232 from 32 pharmaceutical and/or device companies across 893 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Grewal is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 14 years in practice ▲ Top 1% volume in CA $336,232 industry payments

Medicare Practice Summary

Medicare Utilization ↗
262,760
Medicare services
Top 1% in CA for rheumatology
863
Unique beneficiaries
$6
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~18,769 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Certolizumab injection (Cimzia)
An injection of certolizumab pegol administered under the direct supervision of a physician.
232,840 $4 $20
Golimumab infusion (Simponi Aria)
Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery.
18,725 $11 $50
Abatacept infusion (Orencia)
An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered.
6,175 $34 $100
Denosumab injection (Prolia/Xgeva) 2,220 $18 $50
Non-hormonal chemotherapy injection
This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue.
1,168 $77 $200
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
465 $140 $400
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
458 $110 $235
Additional hour of intravenous chemotherapy
This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period.
149 $29 $200
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
107 $14 $50
Telephone medical discussion, 11-20 minutes
A phone conversation with a physician lasting between 11 and 20 minutes.
96 $78 $235
Steroid injection (triamcinolone)
A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered.
89 $1 $13
Intravenous drug injection
A procedure involving the administration of a medication or substance directly into a vein.
81 $39 $100
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
69 $142 $450
Methylprednisolone acetate injection, 80 mg
An injection of 80 mg of methylprednisolone acetate, a corticosteroid medication.
43 $9 $50
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
29 $76 $145
Ultrasound-guided large joint aspiration or injection
This procedure uses ultrasound imaging to guide the removal of fluid from or the injection of medication into a large joint.
28 $99 $244
Methylprednisolone acetate injection, 20 mg
A 20 mg injection of methylprednisolone acetate, a corticosteroid medication. This code specifies the drug and dosage administered.
18 $5 $30
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
9.7% high complexity
90.1% medium
0.2% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$336,232
Total received (2018-2024)
Avg $48,033/year across 7 years
Top 3% in CA for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
32
Companies
893
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$315,671 (93.9%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,576 (3.7%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$7,986 (2.4%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$35,670
2023
$66,939
2022
$63,036
2021
$69,032
2020
$30,411
2019
$40,709
2018
$30,436

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$12,976
GlaxoSmithKline, LLC.
$6,553
UCB, Inc.
$6,238
AstraZeneca Pharmaceuticals LP
$5,823
Amgen Inc.
$3,558
GENZYME CORPORATION
$181
ABBVIE INC.
$69
Aurinia Pharma U.S., Inc.
$66
PFIZER INC.
$47
E.R. Squibb & Sons, L.L.C.
$45
Novartis Pharmaceuticals Corporation
$45
ANI Pharmaceuticals, Inc.
$30
Boehringer Ingelheim Pharmaceuticals, Inc.
$23
Medtronic, Inc.
$15
Top 3 companies account for 72.2% of 2024 payments
All-time payments by company (2018-2024) ›
Horizon Therapeutics plc
$167,074
UCB, Inc.
$61,976
Janssen Biotech, Inc.
$34,519
Horizon Pharma plc
$21,306
AbbVie, Inc.
$15,473
GlaxoSmithKline, LLC.
$11,887
AstraZeneca Pharmaceuticals LP
$6,561
Janssen Scientific Affairs, LLC
$6,228
Amgen Inc.
$5,041
Novartis Pharmaceuticals Corporation
$1,643
Janssen Global Services, LLC
$1,400
PFIZER INC.
$422
ABBVIE INC.
$350
Lilly USA, LLC
$309
E.R. Squibb & Sons, L.L.C.
$296
Celgene Corporation
$260
Boehringer Ingelheim Pharmaceuticals, Inc.
$245
GENZYME CORPORATION
$224
AbbVie Inc.
$190
Aurinia Pharma U.S., Inc.
$159
Oxford Immunotec USA Inc
$146
Alexion Pharmaceuticals, Inc.
$142
Genentech USA, Inc.
$130
Mallinckrodt Hospital Products Inc.
$51
Merck Sharp & Dohme Corporation
$48
ANI Pharmaceuticals, Inc.
$30
FIDIA PHARMA USA INC.
$28
Mallinckrodt Enterprises LLC
$26
Bioventus LLC
$23
Actelion Pharmaceuticals US, Inc.
$18
Medtronic, Inc.
$15
Hikma Pharmaceuticals USA
$11
Top 3 companies account for 78.4% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AVSOLA · BENLYSTA · Bimzelx · COSENTYX · Cimzia · EVENITY · EVUSHELD · Enbrel · FORTEO · HUMIRA · Humira · Hymovis · INFLECTRA · KEVZARA · KRYSTEXXA · LIGASURE · LUPKYNIS · LYRICA · Mitigare · OFEV · OPSUMIT · ORENCIA · Otezla · PURIFIED CORTROPHIN GEL · Prolia · RAYOS · REMICADE · RENFLEXIS · RHEUMATOID ARTHRITIS DISEASE · RINVOQ · Rinvoq · Rituxan · SAPHNELO · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · Strensiq · Supartz Fx Sodium Hyaluronate · TALTZ · TEPEZZA · TREMFYA · TSPOT TB TEST · XELJANZ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (94%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in rheumatology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 3% for rheumatology in CA.

Looking for a rheumatology specialist in West Hollywood?
Compare rheumatologists in the West Hollywood area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
204
Per 100K population
2.1
County median income
$87,760
Nearest hospital
CEDARS-SINAI MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Grewal is a mixed practice specialist, with above-average Medicare volume (top 1% in CA), with speaking/promotional industry engagement in the top 3% of CA peers.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Grewal experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Grewal performed 232,840 certolizumab injection (cimzia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Grewal receive payments from pharmaceutical companies?
Yes. Dr. Grewal received a total of $336,232 from 32 companies across 893 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Grewal's costs compare to other rheumatologists in West Hollywood?
Dr. Grewal's average Medicare payment per service is $6. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Grewal) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →